Trial reportProteomics2011
Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects.
Trial report in Proteomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Plasma biomarker proteins for detection of human growth hormone administration in athletes.Scientific reports · 2017Trial
- Longitudinal Hemoglobin Trajectories and Their Association with Growth Response in Short Stature Children (Aged <15 Years) Undergoing Weekly Growth Hormone Therapy: A Real-World Cohort Study.International journal of general medicine · 2025Article
- The Proteomic Signature of Recombinant Growth Hormone in Recreational Athletes.Journal of the Endocrine Society · 2021Article
- Coupling Complete Blood Count and Steroidomics to Track Low Doses Administration of Recombinant Growth Hormone: An Anti-Doping Perspective.Frontiers in molecular biosciences · 2021Article
- The impact of growth hormone on proteomic profiles: a review of mouse and adult human studies.Clinical proteomics · 2017Review
- A Proteomic Approach for the Identification of Up-Regulated Proteins Involved in the Metabolic Process of the Leiomyoma.International journal of molecular sciences · 2016Article
- A proteomic approach to obesity and type 2 diabetes.Journal of cellular and molecular medicine · 2015Review
- Proteomic analysis allows for early detection of potential markers of metabolic impairment in very young obese children.International journal of pediatric endocrinology · 2014Article
- [Anatomical heterogeneity in the proteome of human subcutaneous adipose tissue].Anales de pediatria (Barcelona, Spain : 2003) · 2013Article
- Multiple protein biomarker assessment for recombinant bovine somatotropin (rbST) abuse in cattle.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The detection of recombinant human growth hormone (rhGH) is difficult due to its short half-life; therefore, novel and robust biomarkers of rhGH abuse are needed. In this study, serum samples derived from subjects treated with rhGH in a randomized, double blind, placebo-controlled crossover study were analyzed by 2-DE coupled with MS. Eight healthy male subjects aged 23.2±0.6 years were injected with rhGH (2 mg/day) or saline for 7 days with serum samples drawn at days 0, 3, and 8. Protein intensities were quantified and analyzed for differences between rhGH and placebo treatments. Proteins that showed significant changes were identified and confirmed by Western blotting. These included specific isoforms of α-1 antitrypsin and transthyretin that increased; and inter-α-trypsin inhibitor heavy chain H4, apolipoprotein A-1, and hemoglobin β chain that decreased. These proteins represent novel biomarkers of short-term rhGH exposure and may lead to a new method for detecting rhGH doping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.